LUNGevity Foundation & Rising Tide Foundation – Lung Cancer Resistance & Recurrence Grants. A joint grant program by LUNGevity and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) supporting early-phase clinical trials that tackle treatment resistance or disease recurrence in lung cancer. This highly competitive award seeks to fund innovative clinical studies that can improve outcomes for lung cancer patients, addressing critical unmet needs such as overcoming therapy resistance or detecting cancer relapse at early stages.
Eligibility Criteria:
- Investigators with a clinical trial proposal in lung cancer (e.g. oncologists or translational researchers with trial-ready projects).
- The project must be an interventional study (Phase I or II) focusing on one of three areas: (1) new treatments to overcome resistance, (2) validating lab-developed tests for monitoring treatment response/resistance, or (3) validating tests for minimal residual disease detection.
- Applicants should demonstrate capability to conduct a clinical trial (access to patient population, institutional support, etc.). Open to international applicants; at least one co-investigator should be based at a recognized cancer research institution.
Funding Details:
- Duration: Up to 4 years of support (multi-year trial funding).
- Amount: Up to $1,000,000 USD total (distributed over the project period). The budget can cover trial-related costs including patient enrollment, data collection, personnel, and correlative research.
- Multiple Awards: Up to 2–3 awards anticipated (exact number depends on available funds and proposal merit).
Deadline:
- February 15, 2026 – Full application due via the online portal by this date. (Note: An initial registration or Letter of Intent may be required by LUNGevity/RTFCCR before full submission; applicants should confirm on the portal.)
Where to go for further information: